Studies on the susceptibility of adult BL6 nude (congenitally athymic, nu/nu) mice, their euthymic littermates (+/nu) and Swiss mice to Japanese encephalitis (JE) virus inoculated subcutaneously were carried out. The mice were observed over a period of 60 days p.i. for sickness and/or death, which was noticed only in nu/nu mice. However, the onset and the duration of sickness varied and no definite pattern was observed. Thirty four of 53 nu/nu, 28 of 42 +/nu and 30 of 52 Swiss mice bled during the first 5 days p.i. exhibited viraemia. Interestingly, only nu/nu mice had secondary viraemia during the period of sickness. The cause of sickness and death in nu/nu mice was confirmed by recovering the virus from the blood, the brain and other organs. Antibodies were detected in the sera of +/nu and Swiss mice from the 10th day p.i. onwards but not in nu/nu mice. These findings indicate the important role of functional T cells both in induction of active immunity and protection against JE virus infection in mice.

Download full-text PDF

Source

Publication Analysis

Top Keywords

nu/nu mice
20
+/nu swiss
12
swiss mice
12
mice
11
bl6 nude
8
nude congenitally
8
congenitally athymic
8
mice japanese
8
japanese encephalitis
8
encephalitis virus
8

Similar Publications

Human cancer cells xenografts to assess the efficacy of granulysin-based therapeutics.

Methods Cell Biol

January 2025

Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, Zaragoza, Spain. Electronic address:

9-kDa Granulysin is a protein present in the granules of human activated cytotoxic T lymphocytes and natural killer cells. It has been shown to exert cytolytic activity against a wide variety of microbes: bacteria, fungi, yeast and protozoa. Recombinant isolated granulysin is also capable of inducing tumor cell death, so it could be used as an anti-tumor therapy.

View Article and Find Full Text PDF

Gastrointestinal stromal tumors (GIST) are the most common mesenchymal malignancy of the gastrointestinal tract. Most GIST harbor mutations in oncogenes, such as KIT, and are treated with tyrosine kinase inhibitors (TKI), such as imatinib. Most tumors develop secondary mutations inducing drug resistance against the available TKI, which requires novel therapies.

View Article and Find Full Text PDF

Efficacy of metformin and verteporfin treatment alone or in combination in a murine head and neck cancer xenograft model.

Eur J Oral Sci

January 2025

Department of Oral Bioscience and Dental Public Health, International College of Dentistry, Walailak University, Bangkok, Thailand.

Despite treatment advances, head and neck squamous cell carcinoma (HNSCC) still poses a significant global health challenge. Combination therapies have emerged as more effective strategies than traditional chemotherapy in clinical practice by improving tumor response rates and patient survival while minimizing treatment-related toxicity. This study investigates the anticancer effects of metformin and verteporfin (Yes-associated protein 1 [YAP1] inhibitor) alone or in combination in HNSCC using vitro and in vivo approaches.

View Article and Find Full Text PDF

Refractory cancer recurrence in patients is a serious challenge in modern medicine. Tumor regrowth in a more aggressive and invasive drug-resistant form is caused by a specific sub-population of tumor cells defined as cancer stem cells (CSCs). While the role of CSCs in cancer relapse is recognized, the signaling pathways of CSCs-driven chemoresistance are less well understood.

View Article and Find Full Text PDF

Anaplastic thyroid carcinoma (ATC) ranks among the most lethal human cancers. Increased migratory and invasive capabilities are critical in malignancy and are often secondary to epithelial-mesenchymal transition (EMT). However, it is not clear whether the invasive behavior of ATC is associated with the presence of EMT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!